3 March 2019 in Bulletin of Russian State Medical University
Ebola virus disease (EVD) is one of the deadliest viral infections affecting humans and nonhuman primates. Of 6 known representatives of the Ebolavirus genus responsible for the disease, 3 can infect humans, causing acute highly contagious fever characterized by up to 90% fatality. These include Bundibugyo ebolavirus (BDBV), Zaire ebolavirus (ZEBOV) and Sudan ebolavirus (SUDV). The majority of the reported EVD cases are caused by ZEBOV. Vaccine development against the virus started in 1976, immediately after the causative agent of the infection was identified. So far, 4 vaccines have been approved. All of them are based on the protective epitope of the ZEBOV glycoprotein GP. Because SUDV and BDBV can also cause outbreaks and epidemics, it is vital to design a vaccine capable of conferring protection against all known ebolaviruses posing a threat to the human population. This article presents systematized data on the structure, immunogenicity and protective properties of ebolavirus glycoprotein GP, looks closely at the immunodominant epitopes of ZEBOV, SUDV and BDBV glycoprotein GP required to elicit a protective immune response, and offers a rational perspective on the development of a universal vaccine against EVD that relies on the use of vectors expressing two variants of GP represented by ZEBOV and SUDV.
1 December 2025 in Molecular Genetics, Microbiology and Virology
The work presents a comparative analysis of imported and Russian components of media and reagents in the cultivation and genetic editing of human lung aden
8 December 2025 in Molecular Genetics Microbiology and Virology (Russian version)
The work presents a comparative analysis of imported and Russian components of media and reagents in the cultivation and genetic editing of human lung adenocarcinoma A549 cells. The study used fetal bovine serum (FBS) from Gibco (USA), Intl Kang (China) and Technozerg (Russia), transfection reagents Lipofectamine3000 (USA) and GenJect39 (Russia), as well as OptiMem (USA) and FectoMEM (Russia) media. Cells cultured on all types of FBS retained high proliferative activity and survival, but the type of FBS had a significant effect on cell morphology. In particular, a fibroblast-like morphology was observed on the Technozerg medium. Transfection efficiency was assessed using the empty pCMV-EGFP expression vector and the CRISPR/Cas9-mediated human lambda DNA polymerase gene editing vector PX458-POLL. OptiMem and FectoMEM media maintained high transfection efficiency with either vector. GenJect39 was as efficient as Lipofectamine3000 for pCMV-EGFP transfection, but GenJect39 was significantly less efficient than Lipofectamine3000 for PX458-POLL genome editing. In addition, the choice of serum was shown to have a significant impact on the ability of cells to form colonies after PX458-POLL transfection. These results indicate that the choice of transfection reagent and FBS play an important role in successful experiment.